UltraHuman Made ₹106 Cr Profit. Revenue Grew 5x. Employee Costs Were ₹37 Cr.

UltraHuman (Ultrahuman Healthcare Private Limited, CIN U74999KA2019PTC129250) reported FY2025 revenue of ₹541.52 Cr, up 447% from ₹98.88 Cr in FY2024. Net profit was ₹106.19 Cr. Gross margin was 56.6%. All figures from audited MCA filings, not press releases.

The Number That Matters

The team cost ₹37 Cr. The profit was ₹106 Cr. Revenue grew 5x.

That is the entire story. Everything else in this filing is the explanation.

---

Three Years of UltraHuman

The pattern is unusual. Consumer tech companies that grow 5x in a year typically do it by spending heavily on customer acquisition or subsidising the product. Losses grow with the revenue. UltraHuman grew 5x and turned profitable simultaneously.

The explanation is in the margin profile. At 56.6% gross margin, every ₹1 of incremental revenue generates ₹0.57 of gross profit. At ₹99 Cr in FY2024 revenue, the gross profit of roughly ₹56 Cr was not enough to cover the fixed cost base. At ₹542 Cr in FY2025 revenue, ₹307 Cr in gross profit more than covered it, with ₹88 Cr remaining as PBT.

---

The 56% Gross Margin

Consumer hardware typically runs 30–45% gross margins in the best cases. Apple achieves approximately 45%. Most hardware startups operating through retail channels target 30–40% at scale.

UltraHuman at 56.6% is in software-company territory.

Three factors likely contribute:

Premium pricing. The Ultrahuman Ring sells at approximately $349 in the US and ₹30,000–35,000 in India. Competing against Oura Ring at similar price points, UltraHuman is positioned at the premium end of the global wearables market. Premium positioning protects gross margins from cost pressure in a way that mass-market consumer electronics cannot.

Possible software and subscription revenue layer. The Ultrahuman platform includes health analytics, sleep tracking, and metabolic monitoring. The ₹29.93 Cr in subscription expenses (what UltraHuman pays for cloud infrastructure to run the platform) implies a significant backend for a user base. If some portion of ₹541.52 Cr in revenue comes from software subscriptions or data services (which have near-zero marginal COGS), the blended gross margin would exceed a pure hardware rate. The filing does not break out hardware vs software revenue.

Global revenue with INR cost base for some manufacturing. At ₹542 Cr in India-reported revenue, a meaningful portion is earned in USD and GBP. If component and manufacturing costs are partially INR-denominated, the FX mix benefits gross margin. The filing does not disclose a currency breakdown.

The 56.6% figure is the composite of all three factors. It is audited.

---

The Cost Structure: Lean Team, Heavy Distribution

UltraHuman's operating cost structure is unusual for a ₹542 Cr company.

Employee costs: ₹37.09 Cr (6.9% of revenue)

₹37 Cr in employee costs on ₹542 Cr revenue implies a small team. At an average total cost of ₹25–35 lakh per person, this suggests approximately 100–150 employees. This is product-led: the Ultrahuman Ring and the associated health platform are built once and scaled without proportionally adding headcount. The product generates revenue; operations stay lean.

Other expenses: ₹323 Cr (the top five items)

Selling and distribution at ₹76.91 Cr is the largest single operating investment after COGS. UltraHuman sells globally: US, UK, Europe, Southeast Asia, India. Distributing physical hardware internationally (warehousing, logistics, customs clearance, last-mile delivery, return handling) at scale is expensive. 14.2% of revenue in distribution costs is consistent with a globally distributed premium hardware product in its early scaling phase.

Job work at ₹42.43 Cr represents outsourced manufacturing or processing charges paid to contract manufacturers. Hardware companies typically outsource assembly and some fabrication. ₹42.43 Cr on ₹235 Cr in net COGS means approximately 18% of the product cost goes to third-party processing. The remainder covers direct materials: sensors, processors, batteries, and titanium or stainless steel casing.

Subscription expenses at ₹29.93 Cr are what UltraHuman pays for cloud services, API access, and software tools to run the health monitoring platform. Running a health data platform for a global user base (continuous sync, sleep analysis algorithms, machine learning inference for health scores) requires substantial cloud infrastructure. ₹30 Cr annually implies a platform with meaningful active usage, not a passive product.

Marketing and advertising at ₹28.67 Cr is conspicuously low for a company that grew 447% in one year. ₹28.67 Cr (5.3% of revenue) spent on marketing to drive ₹542 Cr in revenue implies either strong word-of-mouth and organic demand in the health-conscious consumer segment, or significant channel and retail marketing classified elsewhere under distribution.

---

The Deferred Tax Asset

FY2025 net profit (PAT) of ₹106.19 Cr contains two components: ₹87.97 Cr earned before tax (PBT), and ₹20.18 Cr from deferred tax asset recognition.

A deferred tax asset is created when a company with accumulated tax losses expects to be profitable enough in future years to apply those losses against future taxable income. Recognising a DTA adds to the current year's reported profit. No cash changes hands.

The important point: PBT of ₹87.97 Cr is genuine. The company earned more than it spent, before any accounting adjustment. The DTA of ₹20.18 Cr is additive: it lifts reported PAT to ₹106.19 Cr, but the underlying operating profit is real whether or not the DTA is recognised.

Contrast this with OYO's FY2025 reported profit of ₹233 Cr (PAT), which was primarily DTA-driven on a much smaller PBT base. UltraHuman's profit structure is the reverse: PBT is the primary number, DTA provides a boost on top.

The DTA recognition also signals management's confidence in continued profitability. A company would not recognise a deferred tax asset unless it is confident future profits will materialise to use accumulated tax losses. At ₹88 Cr PBT in FY2025, that confidence is backed by current performance.

---

What Drove the 5x Revenue Jump

Revenue grew from ₹98.88 Cr to ₹541.52 Cr, a ₹442.64 Cr absolute increase in a single year. The filing does not provide a product-level or geography-level breakdown, so the drivers must be inferred.

First full year of global distribution. The Ultrahuman Ring launched internationally in late FY2024 (US launch late 2023, UK and Europe early 2024). FY2025 was the first full year of global sales across all launched markets. Consumer hardware products that achieve product-market fit in the US often see exponential early adoption as initial waitlists convert to purchases. The ₹76.91 Cr in selling and distribution costs supports a global operations footprint already built.

Category validation from Samsung. Samsung launched the Galaxy Ring in July 2024 (mid-FY2025). A large consumer electronics company validating the smart ring form factor by entering the category typically accelerates adoption rather than cannibalising niche players. Consumers who were uncertain about smart rings gain confidence when a major brand validates the segment. UltraHuman's FY2025 jump may partially reflect category tailwinds from Samsung's entry.

Premium positioning in a supply-constrained category. The smart ring category is small relative to smartwatches. Competition for premium health-focused consumers is Oura Ring (the incumbent), Samsung Galaxy Ring (late FY2025 entrant), and UltraHuman. At the price points involved ($349 for UltraHuman), early adopters in the health tech segment are willing to purchase a second or third wearable alongside their existing watch. This reduces zero-sum substitution effects and supports simultaneous revenue growth across competitors.

---

What Must Happen

UltraHuman's FY2025 filing describes a company that has already done what most startups spend years attempting: scaled revenue 5x and became profitable simultaneously. The open questions are forward-looking.

Can the growth rate sustain? Revenue grew 447% in FY2025. The FY2024 base was ₹99 Cr. In FY2026, the comparison base is ₹542 Cr (more than five times larger). Sustaining 50% growth (₹813 Cr) would be exceptional for a hardware company at this scale. Sustaining 100% growth (₹1,084 Cr) would require significant new market entry or new product lines. The filing does not disclose guidance or product pipeline.

Will the margin hold at scale? 56.6% gross margin is high enough to sustain profitability even if margins compress 5–10 percentage points. But selling and distribution costs at 14.2% of revenue could grow faster than revenue as UltraHuman enters markets with higher distribution costs. Legal and IP costs at 6.3% will likely grow in absolute terms as the IP portfolio expands into new jurisdictions. The profitability structure is sound; the question is whether the margin profile compresses at higher scale.

At ₹402 Cr in net worth and ₹88 Cr in annual PBT, UltraHuman has the financial position to fund its next phase without dilution. The FY2025 filing captures a company at an inflection point that most Indian startups never reach: profitable, growing rapidly, and self-funded.